2 weeks Ago By ABMN Staff
Scientech Research LLC purchased a new position in shares of Illumina, Inc. ( NASDAQ:ILMN – Free Report ) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 8,655 shares of the life sciences company’s stock, valued at approximately $903,000.
Other institutional investors and hedge funds also recently made changes to their positions in the company. Envestnet Portfolio Solutions Inc. grew its stake in shares of Illumina by 426.
0% during the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 15,460 shares of the life sciences company’s stock worth $2,123,000 after acquiring an additional 12,521 shares during the period.
Findlay Park Partners LLP bought a new position in Illumina in the 1st quarter worth about $100,120,000. Jupiter Asset Management Ltd. bought a new position in Illumina in the 1st quarter worth about $4,527,000.
US Bancorp DE boosted its stake in Illumina by 33.9% in the 1st quarter. US Bancorp DE now owns 31,600 shares of the life sciences company’s stock worth $4,339,000 after purchasing an additional 8,001 shares during the period.
Finally, BNP Paribas Financial Markets boosted its stake in Illumina by 41.4% in the 1st quarter. BNP Paribas Financial Markets now owns 390,035 shares of the life sciences company’s stock worth $53,560,000 after purchasing an additional 114,263 shares during the period.
Institutional investors own 89.42% of the company’s stock. Illumina Stock Performance Shares of NASDAQ ILMN opened at $130.
12 on Friday. The stock has a market cap of $20.73 billion, a price-to-earnings ratio of -15.
97 and a beta of 1.15. The company has a current ratio of 1.
11, a quick ratio of 0.86 and a debt-to-equity ratio of 1.04.
Illumina, Inc. has a 1-year low of $89.00 and a 1-year high of $148.
19. The stock’s 50-day moving average is $126.36 and its 200 day moving average is $120.
44. Analyst Upgrades and Downgrades ILMN has been the subject of several analyst reports. Evercore ISI cut their target price on Illumina from $195.
00 to $175.00 and set an “outperform” rating for the company in a research note on Tuesday, June 11th. Royal Bank of Canada restated an “outperform” rating and issued a $242.
00 target price on shares of Illumina in a research note on Wednesday, August 14th. StockNews.com initiated coverage on Illumina in a research note on Thursday, August 29th.
They issued a “buy” rating for the company. UBS Group raised their target price on Illumina from $131.00 to $133.
00 and gave the stock a “neutral” rating in a research note on Wednesday, August 7th. Finally, Argus upgraded Illumina from a “hold” rating to a “buy” rating and set a $150.00 price target for the company in a research report on Wednesday, August 28th.
One analyst has rated the stock with a sell rating, nine have assigned a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $151.
05. Check Out Our Latest Analysis on ILMN About Illumina ( Free Report ) Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments.
The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest. Featured Articles Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc.
( NASDAQ:ILMN – Free Report ). Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter .
.
